Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameAscentage
Stock Code06855
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities一間放眼全球的臨床階段生物科技公司,從事開發治療癌症、乙型肝炎病毒(HBV)及衰老相關疾病的新型療法。已研發出包括八項處於臨床階段的小分子候選藥物在內的豐富在研產品,涵蓋蛋白-蛋白相互作用(PPI)及下一代酪氨酸激酶抑制劑(TKI)。
Listing Date2019-10-28
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)江蘇省蘇州市蘇州工業園區星湖街218號B7樓7層
Business Address (Hong Kong)香港中環皇后大道中149號華源大廈9樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websiteascentagepharma.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 34.20 / shares
Offer Price RangeTo be extracted
Lot Size100 shares
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2019-10-16 to 2019-10-21
Global Offering Shares12,180,900 shares
HK Public Offer Shares (Initial)1,218,200 shares (10.0%)
Public Offer Lots (Initial)12,182lots (Pool A6,091lots,Pool B6,091lots)
International Placing Shares (Initial)10,962,700 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO207,074,627 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share37.6%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 416,586,780

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 100 HK$ 3,420
2 lots 200 HK$ 6,840
3 lots 300 HK$ 10,260
4 lots 400 HK$ 13,680
5 lots 500 HK$ 17,100
6 lots 600 HK$ 20,520
7 lots 700 HK$ 23,940
8 lots 800 HK$ 27,360
9 lots 900 HK$ 30,780
10 lots 1,000 HK$ 34,200
20 lots 2,000 HK$ 68,400
30 lots 3,000 HK$ 102,600
40 lots 4,000 HK$ 136,800
50 lots 5,000 HK$ 171,000
60 lots 6,000 HK$ 205,200
70 lots 7,000 HK$ 239,400
80 lots 8,000 HK$ 273,600
90 lots 9,000 HK$ 307,800
100 lots 10,000 HK$ 342,000
200 lots 20,000 HK$ 684,000
300 lots 30,000 HK$ 1,026,000
400 lots 40,000 HK$ 1,368,000
500 lots 50,000 HK$ 1,710,000
600 lots 60,000 HK$ 2,052,000
700 lots 70,000 HK$ 2,394,000
800 lots 80,000 HK$ 2,736,000
900 lots 90,000 HK$ 3,078,000
1,000 lots 100,000 HK$ 3,420,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
2,000 lots 200,000 HK$ 6,840,000
3,000 lots 300,000 HK$ 10,260,000
4,000 lots 400,000 HK$ 13,680,000
5,000 lots 500,000 HK$ 17,100,000
6,000 lots 600,000 HK$ 20,520,000
6,091 lots 609,100 HK$ 20,831,220

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 13.87B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣345.3百萬元
Period-End Cash Balance人民幣957.1百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO Investment人民幣14億元

Financial Data

Unit: '000 RMB
Income Statement
Item 2016-12
Other income and gains, net 218
Administrative expenses -1,292
Profit before tax -8,464
Income tax expense 0
Profit for the year -8,464
Balance Sheet
Item 2016-122016201720182019-06
Cash and cash equivalents 6,097
Total current assets 6,841
Total current liabilities 10,439
Total equity -9,629
Interest-bearing borrowings 8304,89842,044120,114
Cash Flow Statement
Item 2016-122016201720182019-06
Net cash from operating activities 1,250
Net cash from investing activities -225
Net increase in cash 1,025
Depreciation of PP&E 1,0853,9247,6404,760
Depreciation of right-of-use assets 4552,1574,0984,197
Amortisation of intangible assets 76,4206,7243,479
Purchase of PP&E -3,285-20,536-14,257-17,050
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 37.6
First Day OpenHK$ 53.0
First Day Change9.94%
First Day Volume13246000.0
First Day Turnover594180000.0
Use of Proceeds
1、所得款項凈額約42%(約130.9百萬港元)分配到研發,將核心產品HQP1351商業化 2、所得款項凈額約13%(約40.5百萬港元)用于APG-1252持續及規劃臨床試驗; 3、所得款項凈額約19%(約59.2百萬港元)用于APG-2575持續及規劃臨床試驗; 4、所得款項凈額約19%(約59.2百萬港元)用于APG-115持續及規劃臨床試驗; 5、所得款項凈額約6%(約18.7百萬港元)分配到APG-1387及APG-2449其余臨床計劃的持續及規劃臨床試驗; 6、所得款項凈額約1%(約3.1百萬港元)分配到我們的營運資金及一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
Merrill Lynch (Asia Pacific) Limited CE AAC198 Citigroup Global Markets Asia Limited CE AAA137
Overall Coordinators (3)
Merrill Lynch (Asia Pacific) Limited CE AAC198 Citigroup Global Markets Asia Limited CE AAA137 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Joint Bookrunners (7)
Merrill Lynch (Asia Pacific) Limited CE AAC198 Citigroup Global Markets Asia Limited CE AAA137 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 建银国际金融有限公司 CE AJO225 China Renaissance Securities (Hong Kong) Limited CE AZX839 CMB International Capital Holdings Corporation Limited CE AJB801 海通国际证券有限公司 CE AAF806
Joint Lead Managers (7)
Merrill Lynch (Asia Pacific) Limited CE AAC198 Citigroup Global Markets Asia Limited CE AAA137 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 建银国际金融有限公司 CE AJO225 China Renaissance Securities (Hong Kong) Limited CE AZX839 CMB International Capital Holdings Corporation Limited CE AJB801 海通国际证券有限公司 CE AAF806

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 中国生物制药有限公司 156,854,880 HKD — 37.65% — 6 months 2020-04-28

Directors & Management

PositionChinese nameEnglish Name
Chairman楊大俊—
Company Secretary王章旗—
No director data available.

Major Shareholders

Major Shareholders & Holdings楊博士、王博士、郭博士、翟博士及創辦人特殊目的公司、翟博士特殊目的公司為一致行動人,合共持有約32.45%股權;田源博士透過受控法團持有約9.87%及實益持有0.14%;先進製造產業投資有限公司持有約9.21%。
About this page

This page shows Ascentage (06855) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect